Until the end of 2020, two pan-PI3K inhibitors, i.e., copanlisib and duvelisib, and two isoform-selective PI3K inhibitors, i.e., idelalisib and alpelisib, were approved for cancer treatment by the Food and Drug Administration (FDA) (Figure 2). The gene discussed is PIK3CA; the disease is cancer.